Cargando…

Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicentre study

BACKGROUND: Current histopathological staging procedures in colon carcinomas depend on midline division of the lymph nodes with one section of haematoxylin & eosin (H&E) staining only. By this method, tumour deposits outside this transection line may be missed and could lead to understaging...

Descripción completa

Detalles Bibliográficos
Autores principales: Croner, R S, Geppert, C-I, Bader, F G, Nitsche, U, Späth, C, Rosenberg, R, Zettl, A, Matias-Guiu, X, Tarragona, J, Güller, U, Stürzl, M, Zuber, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021519/
https://www.ncbi.nlm.nih.gov/pubmed/24722182
http://dx.doi.org/10.1038/bjc.2014.170
_version_ 1782316250981990400
author Croner, R S
Geppert, C-I
Bader, F G
Nitsche, U
Späth, C
Rosenberg, R
Zettl, A
Matias-Guiu, X
Tarragona, J
Güller, U
Stürzl, M
Zuber, M
author_facet Croner, R S
Geppert, C-I
Bader, F G
Nitsche, U
Späth, C
Rosenberg, R
Zettl, A
Matias-Guiu, X
Tarragona, J
Güller, U
Stürzl, M
Zuber, M
author_sort Croner, R S
collection PubMed
description BACKGROUND: Current histopathological staging procedures in colon carcinomas depend on midline division of the lymph nodes with one section of haematoxylin & eosin (H&E) staining only. By this method, tumour deposits outside this transection line may be missed and could lead to understaging of a high-risk group of stage UICC II cases, which recurs in ∼20% of cases. A new diagnostic semiautomated system, one-step nucleic acid amplification (OSNA), detects cytokeratin (CK) 19 mRNA in lymph node metastases and enables the investigation of the whole lymph node. The objective of this study was to assess whether histopathological pN0 patients can be upstaged to stage UICC III by OSNA. METHODS: Lymph nodes from patients who were classified as lymph node negative after standard histopathology (single (H&E) slice) were subjected to OSNA. A result revealing a CK19 mRNA copy number >250, which makes sure to detect mainly macrometastases and not isolated tumour cells (ITC) or micrometastases only, was regarded as positive for lymph node metastases based on previous threshold investigations. RESULTS: In total, 1594 pN0 lymph nodes from 103 colon carcinomas (median number of lymph nodes per patient: 14, range: 1–46) were analysed with OSNA. Out of 103 pN0 patients, 26 had OSNA-positive lymph nodes, resulting in an upstaging rate of 25.2%. Among these were 6/37 (16.2%) stage UICC I and 20/66 (30.3%) stage UICC II patients. Overall, 38 lymph nodes were OSNA positive: 19 patients had one, 3 had two, 3 had three, and 1 patient had four OSNA-positive lymph nodes. CONCLUSIONS: OSNA resulted in an upstaging of over 25% of initially histopathologically lymph node-negative patients. OSNA is a standardised, observer-independent technique, allowing the analysis of the whole lymph node. Therefore, sampling bias due to missing investigation of certain lymph node tissue can be avoided, which may lead to a more accurate staging.
format Online
Article
Text
id pubmed-4021519
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-40215192015-05-13 Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicentre study Croner, R S Geppert, C-I Bader, F G Nitsche, U Späth, C Rosenberg, R Zettl, A Matias-Guiu, X Tarragona, J Güller, U Stürzl, M Zuber, M Br J Cancer Molecular Diagnostics BACKGROUND: Current histopathological staging procedures in colon carcinomas depend on midline division of the lymph nodes with one section of haematoxylin & eosin (H&E) staining only. By this method, tumour deposits outside this transection line may be missed and could lead to understaging of a high-risk group of stage UICC II cases, which recurs in ∼20% of cases. A new diagnostic semiautomated system, one-step nucleic acid amplification (OSNA), detects cytokeratin (CK) 19 mRNA in lymph node metastases and enables the investigation of the whole lymph node. The objective of this study was to assess whether histopathological pN0 patients can be upstaged to stage UICC III by OSNA. METHODS: Lymph nodes from patients who were classified as lymph node negative after standard histopathology (single (H&E) slice) were subjected to OSNA. A result revealing a CK19 mRNA copy number >250, which makes sure to detect mainly macrometastases and not isolated tumour cells (ITC) or micrometastases only, was regarded as positive for lymph node metastases based on previous threshold investigations. RESULTS: In total, 1594 pN0 lymph nodes from 103 colon carcinomas (median number of lymph nodes per patient: 14, range: 1–46) were analysed with OSNA. Out of 103 pN0 patients, 26 had OSNA-positive lymph nodes, resulting in an upstaging rate of 25.2%. Among these were 6/37 (16.2%) stage UICC I and 20/66 (30.3%) stage UICC II patients. Overall, 38 lymph nodes were OSNA positive: 19 patients had one, 3 had two, 3 had three, and 1 patient had four OSNA-positive lymph nodes. CONCLUSIONS: OSNA resulted in an upstaging of over 25% of initially histopathologically lymph node-negative patients. OSNA is a standardised, observer-independent technique, allowing the analysis of the whole lymph node. Therefore, sampling bias due to missing investigation of certain lymph node tissue can be avoided, which may lead to a more accurate staging. Nature Publishing Group 2014-05-13 2014-04-10 /pmc/articles/PMC4021519/ /pubmed/24722182 http://dx.doi.org/10.1038/bjc.2014.170 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Molecular Diagnostics
Croner, R S
Geppert, C-I
Bader, F G
Nitsche, U
Späth, C
Rosenberg, R
Zettl, A
Matias-Guiu, X
Tarragona, J
Güller, U
Stürzl, M
Zuber, M
Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicentre study
title Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicentre study
title_full Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicentre study
title_fullStr Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicentre study
title_full_unstemmed Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicentre study
title_short Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicentre study
title_sort molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (osna) results in upstaging of a quarter of patients in a prospective, european, multicentre study
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021519/
https://www.ncbi.nlm.nih.gov/pubmed/24722182
http://dx.doi.org/10.1038/bjc.2014.170
work_keys_str_mv AT cronerrs molecularstagingoflymphnodenegativecoloncarcinomasbyonestepnucleicacidamplificationosnaresultsinupstagingofaquarterofpatientsinaprospectiveeuropeanmulticentrestudy
AT geppertci molecularstagingoflymphnodenegativecoloncarcinomasbyonestepnucleicacidamplificationosnaresultsinupstagingofaquarterofpatientsinaprospectiveeuropeanmulticentrestudy
AT baderfg molecularstagingoflymphnodenegativecoloncarcinomasbyonestepnucleicacidamplificationosnaresultsinupstagingofaquarterofpatientsinaprospectiveeuropeanmulticentrestudy
AT nitscheu molecularstagingoflymphnodenegativecoloncarcinomasbyonestepnucleicacidamplificationosnaresultsinupstagingofaquarterofpatientsinaprospectiveeuropeanmulticentrestudy
AT spathc molecularstagingoflymphnodenegativecoloncarcinomasbyonestepnucleicacidamplificationosnaresultsinupstagingofaquarterofpatientsinaprospectiveeuropeanmulticentrestudy
AT rosenbergr molecularstagingoflymphnodenegativecoloncarcinomasbyonestepnucleicacidamplificationosnaresultsinupstagingofaquarterofpatientsinaprospectiveeuropeanmulticentrestudy
AT zettla molecularstagingoflymphnodenegativecoloncarcinomasbyonestepnucleicacidamplificationosnaresultsinupstagingofaquarterofpatientsinaprospectiveeuropeanmulticentrestudy
AT matiasguiux molecularstagingoflymphnodenegativecoloncarcinomasbyonestepnucleicacidamplificationosnaresultsinupstagingofaquarterofpatientsinaprospectiveeuropeanmulticentrestudy
AT tarragonaj molecularstagingoflymphnodenegativecoloncarcinomasbyonestepnucleicacidamplificationosnaresultsinupstagingofaquarterofpatientsinaprospectiveeuropeanmulticentrestudy
AT gulleru molecularstagingoflymphnodenegativecoloncarcinomasbyonestepnucleicacidamplificationosnaresultsinupstagingofaquarterofpatientsinaprospectiveeuropeanmulticentrestudy
AT sturzlm molecularstagingoflymphnodenegativecoloncarcinomasbyonestepnucleicacidamplificationosnaresultsinupstagingofaquarterofpatientsinaprospectiveeuropeanmulticentrestudy
AT zuberm molecularstagingoflymphnodenegativecoloncarcinomasbyonestepnucleicacidamplificationosnaresultsinupstagingofaquarterofpatientsinaprospectiveeuropeanmulticentrestudy